Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

Abstract

Recent studies have implicated fatty acid-dependent activation of the serine kinase IKKβ, which plays a key role in tissue inflammation, in the pathogenesis of insulin resistance. High doses of salicylates have recently been shown to inhibit IKKβ activity and might therefore ameliorate insulin resistance and improve glucose tolerance in patients with type 2 diabetes. To test this hypothesis, we studied nine type 2 diabetic subjects before and after 2 weeks of treatment with aspirin (∼7 g/d). Subjects underwent mixed-meal tolerance tests and hyperinsulinemic-euglycemic clamps with [6,6-2H2]glucose to assess glucose turnover before and after treatment. High-dose aspirin treatment resulted in a ∼25% reduction in fasting plasma glucose, associated with a ∼15% reduction in total cholesterol and C-reactive protein, a ∼50% reduction in triglycerides, and a ∼30% reduction in insulin clearance, despite no change in body weight. During a mixed-meal tolerance test, the areas under the curve for plasma glucose and fatty acid levels decreased by ∼20% and ∼50%, respectively. Aspirin treatment also resulted in a ∼20% reduction in basal rates of hepatic glucose production and a ∼20% improvement in insulin-stimulated peripheral glucose uptake under matched plasma insulin concentrations during the clamp. In conclusion, these data support the hypothesis that IKKβ represents a new target for treating type 2 diabetes mellitus.

Overview

Integrity signals

Registry

Crossref · 10.1172/jci0214955

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 3

  1. Ebstein, 1877, Berliner Klinische Wochenschrift, 24, 337
  2. Giugliano, 1982, Diabete Metab, 8, 279
  3. Shulman, 1990, Am J Physiol, 259, E335

Cited by

See all 557

Metadata

Authors
Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoelson, S. E., & Shulman, G. I.
Affiliations
  • Yale University (US)
  • Joslin Diabetes Center (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
Shulman, Gerald I.
Venue
Journal of Clinical Investigation
Published
2002-05-15
Volume
109
Issue
10
Pages
1321-1326
ISSN
0021-9738 (ISSN-L)
OpenAlex
W4246592598
Cited by
557
References
24
Citations by year
2026: 5 · 2025: 7 · 2024: 21 · 2023: 17 · 2022: 12 · 2021: 11 · 2020: 19 · 2019: 12 · 2018: 21 · 2017: 17 · 2016: 24 · 2015: 32 · 2014: 33 · 2013: 24 · 2012: 24
FWCI
16.11
Type
journal article
Language
en
Open access
closed
Locations
Journal of Clinical Investigation (publishedVersion)
Funders
Yale University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
high-dose aspirin, salicylates, type 2 diabetes, glucose metabolism, insulin resistance, IKKβ, serine kinase, fatty acid signaling, glucose turnover, hepatic glucose production, insulin-stimulated glucose uptake, hyperinsulinemic-euglycemic clamp, mixed meal tolerance test, C-reactive protein, triglycerides, cholesterol

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. https://app.cochat.ai/papers/10.1172/jci0214955
The paper
Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoelson, S. E., & Shulman, G. I. (2002). Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Journal of Clinical Investigation. https://doi.org/10.1172/jci0214955

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.